These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 27501966

  • 21. A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.
    Mehdi SA, Perry MC, Herndon JE, Crawford J, Young R, Graziano SL.
    J Interferon Cytokine Res; 1998 Aug; 18(8):623-7. PubMed ID: 9726444
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I, Frutos Pérez-Surio A, Alcácera MA, Andrés R, Salvador MDT.
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [Abstract] [Full Text] [Related]

  • 25. Randomized study of dose or schedule modification of granulocyte colony-stimulating factor in platinum-based chemotherapy for elderly patients with lung cancer.
    Oshita F, Yamada K, Nomura I, Tanaka G, Ikehara M, Noda K.
    Oncol Rep; 2001 Mar; 8(4):861-6. PubMed ID: 11410799
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
    Bond TC, Szabo E, Gabriel S, Klastersky J, Tomey O, Mueller U, Schwartzberg L, Tang B.
    J Oncol Pharm Pract; 2018 Sep; 24(6):412-423. PubMed ID: 28614980
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
    Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC.
    J Clin Oncol; 2002 Feb 01; 20(3):727-31. PubMed ID: 11821454
    [Abstract] [Full Text] [Related]

  • 34. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.
    Shi YK, Chen Q, Zhu YZ, He XH, Wang HQ, Jiang ZF, Chang JH, Liu YP, Wang AL, Luo DY, Zhang Y, Ke XY, Li WL, Zhang WJ, Wang XW, Zhang YP, Wang JM, Liu XQ.
    Anticancer Drugs; 2013 Jul 01; 24(6):641-7. PubMed ID: 23571496
    [Abstract] [Full Text] [Related]

  • 35. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K, Semiglazov V, Krasnozhon D, Davidenko I, Nelyubina L, Nakov R, Stiegler G, Singh P, Schwebig A, Kramer S, Harbeck N.
    Ann Oncol; 2015 Sep 01; 26(9):1948-1953. PubMed ID: 26122726
    [Abstract] [Full Text] [Related]

  • 36. Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg.
    Fontaine C, Claes N, Graas MP, Samani KK, Vuylsteke P, Vulsteke C.
    Acta Clin Belg; 2021 Feb 01; 76(1):10-15. PubMed ID: 31399016
    [Abstract] [Full Text] [Related]

  • 37. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S, Shi YK, Liu P, Han XH, He XH, Cai YM, Chen ZM.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun 01; 28(3):339-44. PubMed ID: 16900629
    [Abstract] [Full Text] [Related]

  • 38. Pegylated recombinant human granulocyte colony-stimulating factor for primary prophylaxis of neutropenia in patients with cervical cancer receiving concurrent chemoradiotherapy: a prospective study.
    You J, Yuan Y, Gu X, Wang W, Li X.
    BMC Cancer; 2024 Jul 12; 24(1):833. PubMed ID: 38997665
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015.
    Li S, Liu J, Guo H, Gawade PL, Kim C, Bensink ME, Chandler D.
    Support Care Cancer; 2020 Jun 12; 28(6):2637-2649. PubMed ID: 31624920
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.